FDA Approves Gilead’s New Single Tablet HIV Regimen

The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc.’s (NASDAQ:GILD) Bixlenvo, a new treatment for adults with HIV who maintain virologic suppression. The medication combines 75 mg of bictegravir and 50 mg of lenacapavir into the smallest...